Table 2.
Correlation of clinicopathological characteristics with PD-L1 expression in primary tumours and paired metastases.
| Characteristic | Primary tumours(P) |
Paired metastases(M) |
P≠Mb | P valuea | ||
|---|---|---|---|---|---|---|
| PD-L1 (+) | P valuea | PD-L1 (+) | P valuea | |||
| Sex [no (%)] | 0.443 | 0.178 | 0.817 | |||
| Male | 16/84 (19.0) | 20/84 (23.8) | 26/84 (31.0) | |||
| Female | 7/27 (25.9) | 10/27 (37.0) | 9/27 (33.3) | |||
| Age [no (%)] | 0.993 | 0.056 | 0.771 | |||
| ≤60 | 12/58 (20.7) | 11/58 (19.0) | 19/58 (32.8) | |||
| ＞60 | 11/53 (20.8) | 19/53 (35.8) | 16/53 (30.2) | |||
| Primary tumour location [no (%)] | 0.830 | 0.319 | 0.924 | |||
| Right colon cancer | 5/26 (19.2) | 9/26 (34.6) | 8/26 (30.7) | |||
| Left colon cancer | 8/85 (21.2) | 21/85 (24.7) | 27/85 (31.7) | |||
| Histopathological grade [no (%)] | 0.886 | 1.000 | 1.000 | |||
| Moderately differentiated | 22/103 (21.4) | 28/103 (27.2) | 32/103 (31.1) | |||
| Poorly differentiated | 1/8 (12.5) | 2/8 (25.0) | 3/8 (37.5) | |||
| Blood vessel invasion [no (%)] | 1.000 | 1.000 | 0.940 | |||
| Positive | 1/5 (20.0) | 1/5 (20.0) | 1/5 (20.0) | |||
| Negative | 22/106 (20.8) | 29/106 (27.4) | 34/106 (32.1) | |||
| K-ras gene [no (%)] | 0.518 | 0.352 | 0.835 | |||
| Wild type | 9/35 (25.7) | 7/35 (20.0) | 12/35 (34.3) | |||
| Mutant type | 8/41 (19.5) | 12/41 (29.3) | 15/41 (36.6) | |||
| MMR/MSI status [no (%)] | 0.633 | 0.385 | 0.676 | |||
| d MMR (MSI-H) | 2/7 (28.6) | 3/7 (42.9) | 3/7 (42.9) | |||
| p MMR (MSI-L/MS-S) | 21/104 (20.2) | 27/104 (26.0) | 32/104 (30.8) | |||
| Metastatic type [no (%)] | 0.479 | 0.760 | 0.968 | |||
| Synchronous metastasis | 15/79 (19.0) | 22/79 (27.8) | 25/79 (31.6) | |||
| Metachronous metastasis | 8/32 (25.0) | 8/32 (25.0) | 10/32 (31.3) | |||
| Metastatic site [no. (%)] | 0.582 | 0.806 | 0.923 | |||
| Lung | 6/22 (27.3) | 7/22 (31.8) | 7/22 (36.4) | |||
| Liver | 15/79 (19.0) | 23/79 (29.1) | 26/79 (31.6) | |||
| Preoperative chemo/radiotherapy for synchronous metastasis [no (%)] | 0.425 | 0.551 | 0.120 | |||
| Yes | 4/13 (30.7) | 5/13 (71.4) | 7/13 (30.8) | |||
| No | 11/66 (16.7) | 17/66 (36.9) | 18/66 (31.8) | |||
| CD4 TIL infiltration [no (%)] | 0.091 | 0.192 | ||||
| Low | 8/56 (14.3) | 14/63 (22.2) | ||||
| High | 15/55 (27.3) | 16/48 (33.3) | ||||
| CD8 TIL infiltration [no (%)] | ＜0.001 | 0.003 | ||||
| Low | 9/85 (10.6) | 14/76 (18.4) | ||||
| High | 14/26 (53.8) | 16/35 (45.7) | ||||
| Discordance of CD4 TIL infiltration between primary and metastatic tumours [no (%)] | 0.736 | |||||
| Yes | 20/66 (30.3) | |||||
| No | 15/45 (33.3) | |||||
| Discordance of CD8 TIL infiltration between primary and metastatic tumours [no (%)] | 0.003 | |||||
| Yes | 16/73 (21.9) | |||||
| No | 19/38 (50.0) | |||||
Note:
a
Chi-square test or Fisher's exact test was used. Bold indicates p < 0.05.
b
P≠M indicates discordant PD-L1 expression in primary tumours and paired metastases.